BPC-157 vs TB-500
The two peptides most frequently discussed together under the "systemic tissue repair" umbrella. Both are associated with tendon, ligament and soft-tissue recovery in preclinical models, but they come from unrelated parent proteins and act through distinct mechanisms.
BPC-157
A 15-amino-acid synthetic peptide fragment derived from a protective protein found in human gastric juice, studied for over three decades in animal models of tendon, ligament, gut and vascular repair.
TB-500 (Thymosin Beta-4)
A research designation commonly applied to synthetic fragments of Thymosin Beta-4, the body's most abundant actin-sequestering peptide, studied for its role in cell migration, angiogenesis and tissue-repair signalling.
Origin and structure
BPC-157 is a synthetic 15-amino-acid pentadecapeptide (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val), a stable fragment derived from a protective protein identified in human gastric juice and characterised through the 1990s by Predrag Sikirić's group at the University of Zagreb.
TB-500 is a research-market name most often applied to a synthetic 17-amino-acid fragment of native Thymosin Beta-4, a 43-amino-acid actin-sequestering peptide first isolated in 1966 by Allan Goldstein's group from calf thymus extract. Commercial material sold as TB-500 is not consistently distinguished from full-length Thymosin Beta-4, and the two should be treated as a market designation rather than a single defined chemical entity.
Mechanism
BPC-157's most-cited mechanism is upregulation of VEGFR2 signalling, promoting angiogenesis in hypovascular tissue such as tendon, alongside modulation of the L-arginine-nitric oxide pathway reported to normalise NO production in injured tissue beds. A further proposed mechanism involves increased growth-hormone receptor expression in tendon fibroblasts.
Thymosin Beta-4's mechanism is comparatively well mapped at the molecular level: it sequesters monomeric G-actin, buffering a pool of polymerisation-ready actin that can be rapidly mobilised into F-actin at the leading edge of a migrating cell. This underpins its effects on keratinocyte, fibroblast and endothelial-cell migration, with angiogenic activity linked to KLF2 upregulation in endothelial cells.
Evidence base
BPC-157's preclinical literature exceeds 100 published studies, concentrated in tendon-to-bone healing (Krivic et al. 2008), gastric-mucosal protection, and more recently hind-limb ischaemia (Vukojević et al. 2020), but there is no completed, published randomised controlled trial in humans at any dose.
Thymosin Beta-4 carries a materially different evidence profile: alongside a substantial preclinical literature — including the widely cited cardiac-regeneration study by Bock-Marquette et al. (Nature, 2004) — it is the subject of a genuine sponsor-run human clinical programme by RegeneRx Biopharmaceuticals (RGN-259), with published phase I/II trials in dry-eye disease and dermal wound healing. This gives TB-500/Thymosin Beta-4 a firmer, if still limited, human safety dataset than BPC-157 can currently offer.
Research positioning
Both peptides are studied as candidate interventions for soft-tissue and tendon repair, and are frequently examined together in research protocols given their overlapping preclinical territory. A key practical distinction for anyone weighing the evidence: Thymosin Beta-4 is also a substance prohibited at all times under the WADA Prohibited List, owing to its growth-factor-like regenerative activity, whereas BPC-157 does not carry equivalent anti-doping designation. Neither compound holds a licensed indication for musculoskeletal repair in any jurisdiction.
Summary table
| Attribute | BPC-157 | TB-500 |
|---|---|---|
| Origin | Fragment of a gastric-protective protein | Fragment/analogue of Thymosin Beta-4 (calf thymus) |
| Length | 15 amino acids | ~17-amino-acid fragment (native Tβ4 is 43 aa) |
| Primary mechanism | VEGFR2 angiogenesis + nitric-oxide modulation | G-actin sequestration; KLF2-mediated angiogenesis |
| Human trial data | None completed and published | RegeneRx phase I/II trials (dry-eye, dermal wounds) |
| Anti-doping status | Not separately listed by WADA | Prohibited at all times under WADA Code |
| UK regulatory status | Not licensed — research only | Not licensed — research only |
For the full evidence base, see the individual pages: Read the full BPC-157 entry and Read the full TB-500 entry.